Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases

Journal of Cellular Biochemistry

Volumn 101, Issue 1, 2007, Pages 205-220

  Trebec, Diana P ^a,b   Chandra, Divya ^b   Gramoun, Azza ^b   Li, Keying ^b   Heersche, Johan N M ^b   Manolson, Morris F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Arthritis; Bone; Cytokines; Inflammation; Osteoclasts

Indexed keywords

BETA3 INTEGRIN; CATHEPSIN K; CD51 ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEINASE; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL FUSION; CELL STRAIN; CONTROLLED STUDY; EXTRACELLULAR MATRIX; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RABBIT; RAT; SIGNAL TRANSDUCTION;

ACID PHOSPHATASE; ANIMALS; ARTHRITIS; CELL LINE; CYTOKINES; ENZYME PRECURSORS; IMMUNOBLOTTING; INFLAMMATION; INTEGRIN ALPHA1BETA1; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; ISOENZYMES; MACROPHAGE COLONY-STIMULATING FACTOR; MATRIX METALLOPROTEINASE 9; MICE; OSTEOCLASTS; RABBITS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

ORYCTOLAGUS CUNICULUS;

EID: 34247468008     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21171     Document Type: Article

References (68)

1. Aota S, Nakamura T, Suzuki K, Tanaka Y, Okazaki Y, Segawa Y, Miura M, Kikuchi S. 1996. Effects of indomethacin administration on bone turnover and bone mass in adjuvant-induced arthritis in rats. Calcif Tissue Int 59:385-391.
2. Arend WP, Dayer JM. 1990. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305-315.
3. Battaglino R, Kim D, Fu J, Vaage B, Fu XY, Stashenko P. 2002. c-myc is required for osteoclast differentiation. J Bone Miner Res 17:763-773.
4. Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM. 2005. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 38:161-170.
5. Blair HC, Robinson LJ, Zaidi M. 2005. Osteoclast signalling pathways. Biochem Biophys Res Commun 328:728-738.
6. 3 integrin, essential to formation of osteoclast-like multinucleated cells. J Cell Sci 111(Pt 17):2563-2574.
7. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
8. Caldwell CB, Moran EL, Bogoch ER. 1998. Fractal dimension as a measure of altered trabecular bone in experimental inflammatory arthritis. J Bone Miner Res 13:978-985.
9. Chiusaroli R, Maier A, Knight MC, Byrne M, Calvi LM, Baron R, Krane SM, Schipani E. 2003. Collagenase cleavage of type I collagen is essential for both basal and parathyroid hormone (PTH)/PTH-related peptide receptor-induced osteoclast activation and has differential effects on discrete bone compartments. Endocrinology 144:4106-4116.
10. Collin-Osdoby P, Yu X, Zheng H, Osdoby P. 2003. RANKL-mediated osteoclast formation from murine RAW 264.7 cells. Methods Mol Med 80:153-166.
11. Dayer JM. 2002. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 69:123-132.
12. Dayer JM. 2003. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl 2):ii3-ii10.
13. Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. 2003. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61:504-513.
14. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
15. Dinarello CA. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16:457-499.
16. Duong LT, Lakkakorpi P, Nakamura I, Rodan GA. 2000. Integrins and signaling in osteoclast function. Matrix Biol 19:97-105.
17. Feldmann M, Brennan FM, Maini RN. 1996. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440.
18. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. 2003. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 10:1165-1177.
19. Ha H, Kwak HB, Lee SK, Na DS, Rudd CE, Lee ZH, Kim HH. 2003. Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. J Biol Chem 278:18573-18580.
20. Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA, Lindberg FP, Vignery A. 2000. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 275:37984-37992.
21. Haynes DR, Atkins GJ, Loric M, Crotti TN, Geary SM, Findlay DM. 1999. Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Bone 25:269-278.
22. Helfrich MH, Nesbitt SA, Horton MA. 1992. Integrins on rat osteoclasts: Characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. J Bone Miner Res 7:345-351.
23. Holliday L, Welgus H, Fliszar C, Veith G, Jeffrey J, Gluck S. 1997. Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 272:22053-22058.
24. Hynes RO. 2002. Integrins: Bidirectional, allosteric signaling machines. Cell 110:673-687.
25. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T. 1998. Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273:8799-8805.
26. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, Suda T. 1999. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 247:84-93.
27. Kalesnikoff J, Sly LM, Hughes MR, Buchse T, Rauh MJ, Cao LP, Lam V, Mui A, Huber M, Krystal G. 2003. The role of SHIP in cytokine-induced signaling. Rev Physiol Biochem Pharmacol 149:87-103.
28. Kanehisa J, Heersche JN. 1988. Osteoclastic bone resorption: In vitro analysis of the rate of resorption and migration of individual osteoclasts. Bone 9:73-79.
29. Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O. 2001. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 28:474-483.
30. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand [In Process Citation]. Nature 402:304-309.
31. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. 2004. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49-60.
32. Lakkakorpi PT, Vaananen HK. 1996. Cytoskeletal changes in osteoclasts during the resorption cycle. Microsc Res Tech 33:171-181.
33. Lees RL, Heersche JN. 1999. Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size. J Bone Miner Res 14:937-945.
34. Lees RL, Heersche JN. 2000. Differences in regulation of pH(i) in large (≥10 nuclei) and small (≤5 nuclei) osteoclasts. Am J Cell Physiol 279:C751-C761.
35. Lees RL, Sabharwal VK, Heersche JN. 2001. Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 28:187-194.
36. Liu Y, Buhring HJ, Zen K, Burst SL, Schnell FJ, Williams IR, Parkos CA. 2002. Signal regulatory protein (SIRPalpha), a cellular ligand for CD47, regulates neutrophil transmigration. J Biol Chem 277:10028-10036.
37. Manolson MF, Yu H, Chen W, Yao Y, Li K, Lees RL, Heersche JN. 2003. The a3 isoform of the 100-kDa V-ATPase subunit is highly but differentially expressed in large (>/=10 nuclei) and small (
38. McCawley LJ, Matrisian LM. 2001. Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 13:534-540.
39. Mori H, Kitazawa R, Mizuki S, Nose M, Maeda S, Kitazawa S. 2002. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol 117:283-292.
40. Nabeshima K, Inoue T, Shimao Y, Sameshima T. 2002. Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int 52:255-264.
41. Nakamura I, Rodan GA, Duongle T. 2003. Regulatory mechanism of osteoclast activation. J Electron Microsc (Tokyo) 52:527-533.
42. Nesbitt S, Nesbit A, Helfrich M, Horton M. 1993. Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. J Biol Chem 268:16737-16745.
43. Nordstrom T, Shrode LD, Rotstein OD, Romanek R, Goto T, Heersche JN, Manolson MF, Brisseau GF, Grinstein S. 1997. Chronic extracellular acidosis induces plasmalemmal vacuolar type H+ ATPase activity in osteoclasts. J Biol Chem 272:6354-6360.
44. Nukaga J, Kobayashi M, Shinki T, Song H, Takada T, Takiguchi T, Kamijo R, Hasegawa K. 2004. Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells. J Periodontol 75:249-259.
45. O'Gradaigh D, Ireland D, Bord S, Compston JE. 2004. Joint erosion in rheumatoid arthritis: Interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 63:354-359.
46. Oshima K, Ruhul Amin AR, Suzuki A, Hamaguchi M, Matsuda S. 2002. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett 519:1-7.
47. Pacifici R, Carano A, Santoro SA, Rifas L, Jeffrey JJ, Malone JD, McCracken R, Avioli LV. 1991. Bone matrix constituents stimulate interleukin-1 release from human blood mononuclear cells. J Clin Invest 87:221-228.
48. Piper K, Boyde A, Jones SJ. 1992. The relationship between the number of nuclei of an osteoclast and its resorptive capability in vitro. Anat Embryol 186:291-299.
49. Roodman GD. 1999. Cell biology of the osteoclast. Exp Hematol 27:1229-1241.
50. Saginario C, Qian HY, Vignery A. 1995. Identification of an inducible surface molecule specific to fusing macrophages. Proc Natl Acad Sci USA 92:12210-12214.
51. Sato K, Takayanagi H. 2006. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 18:419-426.
52. Seiffert M, Brossart P, Cant C, Cella M, Colonna M, Brugger W, Kanz L, Ullrich A, Buhring HJ. 2001. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 97:2741-2749.
53. Sherr CJ, Roussel MF, Rettenmier CW. 1988. Colony-stimulating factor-1 receptor (c-fms). J Cell Biochem 38:179-187.
54. Singer F, Roodman GD. 1996. Paget's disease of bone. In: Bilezikian J, LG R, GA R, editors. Principles of bone biology. San Diego: Academic Press. pp 969-977.
55. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. 1997. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24:365-371.
56. Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. 1999. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest 103:1409-1418.
57. Takayanagi H. 2005. Inflammatory bone destruction and osteoimmunology. J Periodontal Res 40:287-293.
58. Takeshita S, Namba N, Zhao JJ, Jiang Y, Genant HK, Silva MJ, Brodt MD, Helgason CD, Kalesnikoff J, Rauh MJ, Humphries RK, Krystal G, Teitelbaum SL, Ross FP. 2002. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 8:943-949.
59. Tanaka S, Nakamura I, Inoue J, Oda H, Nakamura K. 2003. Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab 21:123-133.
60. Teitelbaum SL, Ross FP. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
61. Troen BR. 2003. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 38:605-614.
62. van der Flier A, Sonnenberg A. 2001. Function and interactions of integrins. Cell Tissue Res 305:285-298.
63. Vignery A. 2000. Osteoclasts and giant cells: Macrophage-macrophage fusion mechanism. Int J Exp Pathol 81:291-304.
64. Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF. 2005. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration. Biochem Pharmacol 70:300-307.
65. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282-290.
66. Wilder RL. 2002. Integrin alphav beta3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61(Suppl 2):ii96-ii99.
67. Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Redini F. 2003. Regulation of osteoclast protease expression by RANKL. Biochem Biophys Res Commun 310:774-778.
68. Xu LX, Kukita T, Nakano Y, Yu H, Hotokebuchi T, Kuratani T, Iijima T, Koga T. 1996. Osteoclasts in normal and adjuvant arthritis bone tissues express the mRNA for both type I and II interleukin-1 receptors. Lab Invest 75:677-687.